Targets › PROC
1 program from 1 company in 4 trials: 3 Phase 4, 1 Phase 3; Cardiovascular, Gastroenterology, Hematology; next expected readout Apr 2027.
Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids. Exerts a protective effect on the endothelial cell barrier function. (UniProt, P04070)
Open in Phaseline: the race on PROC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CSL Behring | Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
Complex Cardiovascular Surgery With Cardiopulmonary Bypass (1) Cardiac Valve Disease (1) Hemophilia (1) Liver Cirrhosis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.